Early Arrhythmic Events in Idiopathic Dilated Cardiomyopathy

JACC: Clinical Electrophysiology

Volumn 2, Issue 5, 2016, Pages 535-543

  Losurdo, Pasquale ^a   Stolfo, Davide ^a   Merlo, Marco ^a   Barbati, Giulia ^a   Gobbo, Marco ^a   Gigli, Marta ^a   Ramani, Federica ^a   Pinamonti, Bruno ^a   Zecchin, Massimo ^a   Finocchiaro, Gherardo ^b   Mestroni, Luisa ^c   Sinagra, Gianfranco ^a  

^a Ospedali Riuniti University Hospital   (Italy)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

arrhythmia; cardiomyopathy; sudden death

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CARDIAC PATIENT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; QRS COMPLEX; RETROSPECTIVE STUDY;

EID: 84993946941     PISSN: 2405500X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacep.2016.05.002     Document Type: Article

References (22)

1. 1 Zecchin, M., Merlo, M., Pivetta, A., et al. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with “SCD-HeFT criteria?”. Am J Cardiol 109 (2012), 729–735.
2. 2 McMurray, J.J., Adamopoulos, S., Anker, S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 (2012), 1787–1847.
3. 3 Elliott, P., Andersson, B., Arbustini, E., et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008), 270–276.
4. 4 Merlo, M., Pivetta, A., Pinamonti, B., et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail 16 (2014), 317–324.
5. 5 Anzini, M., Merlo, M., Sabbadini, G., et al. Long-term evolution and prognostic stratification of biopsy-proven active myocarditis. Circulation 128 (2013), 2384–2394.
6. 6 Mestroni, L., Maisch, B., McKenna, W.J., et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur Heart J 20 (1999), 93–102.
7. 7 Poole-Wilson, P.A., Swedberg, K., Cleland, J.G., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003), 7–13.
8. 8 Nagueh, S.F., Appleton, C.P., Gillebert, T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10 (2009), 165–193.
9. 9 Lancellotti, P., Tribouilloy, C., Hagendorff, A., et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). Eur J Echocardiogr 11 (2010), 223–244.
10. 10 Fishman, G.I., Chugh, S.S., Dimarco, J.P., et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 122 (2010), 2335–2348.
11. 11 Harrell, F.E., Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. 2001, Springer, New York, NY.
12. 12 Heinze, G., Ploner, M., Beyea, J., Confidence intervals after multiple imputation: combining profile likelihood information from logistic regressions. Stat Med 32 (2013), 5062–5076.
13. 13 Daubert, J.P., Lewis, R.K., Smarter deployment of implantable cardioverter-defibrillators in nonischemic cardiomyopathy: feasible or mythical?. J Am Coll Cardiol 63 (2014), 1890–1891.
14. 14 Sheppard, R., Mather, P.J., Alexis, J.D., et al. Implantable cardiac defibrillators and sudden death in recent onset nonischemic cardiomyopathy: results from IMAC2. J Card Fail 18 (2012), 675–681.
15. 15 Kadish, A., Dyer, A., Daubert, J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004), 2151–2158.
16. 16 Bardy, G.H., Lee, K.L., Mark, D.B., et al., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005), 225–237.
17. 17 Kadish, A., Schaechter, A., Subacius, H., Thattassery, E., Sanders, W., Anderson, K.P., Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol 47 (2006), 2477–2482.
18. 18 Goldberger, J.J., Subacius, H., Patel, T., Cunnane, R., Kadish, A.H., Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 63 (2014), 1879–1889.
19. 19 Gulati, A., Jabbour, A., Ismail, T.F., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309 (2013), 896–908.
20. 20 Hombach, V., Merkle, N., Torzewski, J., et al. Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy. Eur Heart J 30 (2009), 2011–2018.
21. 21 Bhat, P.K., Ashwath, M.L., Rosenbaum, D.S., Costantini, O., Usefulness of left ventricular end-systolic dimension by echocardiography to predict reverse remodeling in patients with newly diagnosed severe left ventricular systolic dysfunction. Am J Cardiol 110 (2012), 83–87.
22. 22 Kutyifa, V., Moss, A.J., Klein, H., et al. Use of the Wearable cardioverter defibrillator in high-risk cardiac patients. Data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 132 (2015), 1613–1619.